References

1. Shiraev T, Pasricha SS, Choon P, et al. Retroperitoneal sarcomas: A review of disease spectrum, radiological features, characterisation and management. J Med Imaging Radiat Oncol 2013;57(6):687700.

2. Mullinaux JE, Zager JS, Gonzalez RJ. Current diagnosis and management of retroperitoneal sarcoma. Cancer Control 2011;18(3):17787.

3. Guidelines on Cancer Services. Improving Outcomes for People with Sarcoma. National Institute for Health and Clinical Excellence, London, 2006

4. The European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: EMSO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 8):vii92vii99.

5. Von Mehren M, Randall RL, Bengamin RS, et al. Soft tissue sarcoma, Version 2.2014. J Nat Compr Canc Netw 2014;12(4):47383.

6. Eary JF, Hawkins DS, Rodler ET, Conrad EU III. 18F-FGD PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 2011;1(1):4753.

7. McGrath P. Retroperitoneal sarcomas. Semin Surg Oncol. 1994;10:3648.

8. Pham TH, Iqbal CW, Zarroug AE, Donohue JH, Moir C. Retroperitoneal sarcomas in children: outcomes from an institution. J Pediatr Surg. 2007;42(5):82933.

9. Thomas DM1, O'Sullivan B, Gronchi A. Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther. 2009;9(8):114557.

10. College of American Pathologists. Available from www.cap.org. Accessed 3 June 2013.

11. 15. The Royal College of Pathologists. Available from www.rcpath.org. Accessed 3 June 2013.

12. The Royal College of Pathologists of Australasia. Available from www.rcpa.edu.au. Accessed 3 June 2013.

13. CDM Fletcher, JA Bridge, PCW Hogendoorn , F Mertens. WHO Classification of Tumours of Soft Tissue and Bone. IARC 2013.

14. Bonvalot S, Raut CP, Pollock RE, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery and EORTC-STBSG. Ann Surg Oncol 2012;19(9):298191.

15. Brennan MF, Antonescu CR, Maki RG. Management of Soft Tissue Sarcoma. Springer, New York, 2012.

16. Pawlik TM1, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, Ballo MT, Catton CN, Jones JJ, O'Sullivan B, Pollock RE, Swallow CJ. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13(4):50817.

17. Tzeng CW1, Fiveash JB, Popple RA, Arnoletti JP, Russo SM, Urist MM, Bland KI, Heslin MJ.Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer 2006;107(2):3719.

18. European Organisation for Research and Treatment of Cancer EORTC. Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma (STRASS). In: ClnicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2014 3 June]. Available from: http://clinicaltrials.gov/show/NCT01344018 NLM Identifier: NCT01344018.

19. Gieschen HL1, Spiro IJ, Suit HD, Ott MJ, Rattner DW, Ancukiewicz M, Willett CG. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50(1):12731.

20. Heslin MJ1, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES, Leung D, Brennan MF. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol. 1997;15(8):28329.

21. Grimer R1, Athanasou N, Gerrand C, Judson I, Lewis I, Morland B, Peake D, Seddon B, Whelan J, UK Guidelines for the Management of Bone Sarcomas. Sarcoma 2010: 317462. doi: 10.1155/2010/317462.

22. Tan M, Brennan MF, Agaram NP, Qin LX, Kuk D, Moraco N, Crago AM, Singer S. The importance ofhistologic subtype for outcome prediction in primary retroperitoneal sarcoma: a single institution study of 674 patients. In: Connective Tissue Oncology Society, 18th Annual Meeting, October 30 November 2, 2013, Paper 008.

23.Bramwell V1,Rouesse J,Steward W,Santoro A,Schraffordt-Koops H,Buesa J,Ruka W,Priario J,Wagener T,Burgers M, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):113749.

24.Woll PJ,Reichardt P,Le Cesne A,Bonvalot S,Azzarelli A,Hoekstra HJ,Leahy M,Van Coevorden F,Verweij J,Hogendoorn PC,Ouali M,Marreaud S,Bramwell VH,Hohenberger P;EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13(10):104554.

25.Donahue TR1,Kattan MW,Nelson SD,Tap WD,Eilber FR,Eilber FC. Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram. Cancer 2010 15;116(16):388391.

26.Toulmonde M1,Bonvalot S,Ray-Coquard I,Stoeckle E,Riou O,Isambert N,Bompas E,Penel N,Delcambre-Lair C,Saada E,Lecesne A,Le Pchoux C,Blay JY,Piperno-Neumann S,Chevreau C,Bay JO,Brouste V,Terrier P,Ranchre-Vince D,Neuville A,Italiano A;French Sarcoma Group. Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on mainhistological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol 2014;25(3):7304.

27.Italiano A,Toulmonde M,Cioffi A,Penel N,Isambert N,Bompas E,Duffaud F, Patrikidou A ,Lortal B,Le Cesne A,Blay JY,Maki RG,Schwartz GK,Antonescu CR,Singer S,Coindre JM,Bui B. Advanced well differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 2012;23(6):16017.

28.Jones RL,Fisher C,Al-Muderis O,Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005;41(18):285360.

29. Sirvent N, Coindre JM, Maire G, et al. Detection ofMDM2-CDK4amplification by fluorescencein situhybridization in 200 paraffin-embedded tumor samples: Utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and realtime PCR. Am J Surg Pathol 31:147689, 2007

30. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN.Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients withMDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.Lancet Oncol. 2012;13(11):113340.

31.Dickson MA,Tap WD,Keohan ML,D'Angelo SP,Gounder MM,Antonescu CR,Landa J,Qin LX,Rathbone DD,Condy MM,Ustoyev Y,Crago AM,Singer S,Schwartz GK. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31(16):20248

32.Hensley ML. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol. 2010 Jul;22(4):35661.

33. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gmez J, Park YC, Le Cesne A. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):418896.

34.Garca-Del-Muro X1,Lpez-Pousa A,Maurel J,Martn J,Martnez-Trufero J,Casado A,Gmez-Espaa A,Fra J,Cruz J,Poveda A,Meana A,Pericay C,Cubedo R,Rubi J,De Juan A,Lanez N,Carrasco JA,de Andrs R,Buesa JM;Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29(18):252833.

35.Park MS,Patel SR,Ludwig JA,Trent JC,Conrad CA,Lazar AJ,Wang WL,Boonsirikamchai P,Choi H,Wang X,Benjamin RS,Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):493947.

36.Stacchiotti S1,Negri T,Libertini M,Palassini E,Marrari A,De Troia B,Gronchi A,Dei Tos AP,Morosi C,Messina A,Pilotti S,Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23(12):31719.

37. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2012;379(9829):187986.